Cell Biology Program
The Xuejun Jiang Lab
Research

The research of my laboratory focuses on two directions highly relevant to cancer biology, (1) the molecular basis of programmed cell death processes (including apoptosis and ferroptosis), and their roles in human disease; and (2) the molecular basis of autophagy and its role in cancer. We also study various cancer signaling and cellular metabolic events, especially those involved in cell death/survival determination. We aim to translate our basic research finding into potential therapeutic approaches. To achieve these goals, the laboratory utilizes a combination of approaches including biochemistry, chemical biology, proteomics, molecular cell biology, high-throughput screening, 3-dimensional microfluidic cell array, and mouse modeling.

Featured News


Publications
People

Xuejun Jiang, PhD
- Cell biologist Xuejun Jiang studies programmed cell death, molecular mechanisms, and their roles in tumorigenesis.
- PhD, University of Texas Southwestern Medical Center at Dallas
- [email protected]
- Email Address
- 212-639-6814
- Office Phone
Members



- PhD, Nankai University, China
- 212-639-7339
- Lab Phone

Administrative Assistant

Research Scholar

Lab Head

Graduate Student, WCMC

Research Associate

Graduate Student, WCMC

Research Fellow

Research Scholar

Postdoctoral Fellow

Graduate Student, WCMC





- University of Georgia

- Hunter College



Lab Alumni

University Assistant at Johannes Kepler University

Visiting Investigator
Graduate Student

Chancellor's Fellow at Edingburg Cancer Research Center
Programme Leader at MRC Protein Phosphorylation and Ubiquitylation Unit, University of Dundee

Principal Investigator at Harbin Institute of Technology
Assistant Professor, Department of Biochemistry and Molecular Biology, Penn State Cancer Institute
Research Scientist, MSKCC
Postdoc Research Fellow at Ben Gurion University of the Negev, Israel

Medical Writer in Regulatory Affairs at Regeneron Pharmaceuticals, Inc.

Senior Scientist at Wave Life Sciences, Boston, MA

VP of Scientific Services, PRI Healthcare Solutions, Parisppany, NJ
President and Founder of Bon Opus Biosciences

Senior Scientist at Pfizer
Vice Director at Zhangjiagang Hospital

Senior Research Technician
Principal Investigator at Roswell Park Cancer Institute


Professor at Fourth Military Medical University, Xi'an

Research Scholar
Program Manager at Center Ministry of Science and Technology, China
Professor at Air Force Military Medical University, China
Lab Affiliations
Achievements
- Louis and Allston Boyer Young Investigator Award for Basic Research, Memorial Sloan Kettering Cancer Center (2007)
- Scholar, American Cancer Society (2007-2010)
- Catherine and Frederick Adler Chair for junior faculty, Memorial Sloan Kettering Cancer Center (2006)
- V Scholar, The V Foundation for Cancer Research (2004-2006 )
- Alfred Bressler Scholar, Alref W. Bresller Scholars Fund (2004-2007)
Read more
- Sigma Xi Award, UT Southwestern (1998)
- Robert A. Welch Predoctoral Fellowship, UT Southwestern (1995-1999)
Open Positions
To learn more about available postdoctoral opportunities, please visit our Career Center
Career Opportunities
Get in Touch
-
Lab Head Email
-
Office Phone
-
Office Fax
Disclosures
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Xuejun Jiang discloses the following relationships and financial interests:
-
Exarta Therapeutics
Fiduciary Role/Position; Ownership / Equity Interests; Provision of Services
-
VivoZ Biolabs, LLC
Intellectual Property Rights; Provision of Services (uncompensated)
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.
Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].